1
Michael R Myers, Alfred P Spada, Martin P Maguire, Paul E Persons, Asher Zilberstein, Chin Yi Jenny Hsu, Susan E Johnson: Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase. Rhone Poulenc Rorer Pharmaceuticals, Raymond S Parker III, James A Nicholson, Martin F Savitzky, February 3, 1998: US05714493 (79 worldwide citation)

This invention relates to the treatment of intimation in a patient suffering from such disorder. More specifically, the invention relates to mono- and/or bicyclic aryl or heteroaryl quinazoline compounds in the treatment of inflammation.


2
Michael R Myers, Alfred P Spada, Martin P Maguire, Paul E Persons, Asher Zilberstein, Chin Yi Jenny Hsu, Susan E Johnson: Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase. Aventis Pharmaceuticals, Raymond S Parker III, Peter J Butch, November 11, 2003: US06645969 (31 worldwide citation)

This invention relates to the modulation and/or inhibition of cell signaling, cell proliferation, cell inflammatory response, the control of abnormal cell growth and cell reproduction. More specifically, this invention relates to the use of mono- and/or bicyclic aryl or heteroaryl quinazoline compou ...


3
Michael R Myers, Alfred P Spada, Martin P Maguire, Paul E Persons, Asher Zilberstein, Chin Yi Jenny Hsu, Susan E Johnson: Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase. Aventis Pharmacetical Products, Synnestvedt & Lechner, April 9, 2002: USRE037650

This invention relates to the treatment of intimation in a patient suffering from such disorder. More specifically, the invention relates to mono- and/or bicyclic aryl or heteroaryl quinazoline compounds in the treatment of inflammation.


4

5
Michael R Myers, Alfred P Spada, Martin P Maguire, Paul E Persons, Asher Zilberstein, Chin Yi Jenny Hsu, Susan E Johnson: Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase. Synnestvedt Lechner & Woodbridge, January 22, 2004: US20040014774-A1

This invention relates to the modulation and/or inhibition of cell signaling, cell proliferation, cell inflammatory response, the control of abnormal cell growth and cell reproduction. More specifically, this invention relates to the use of mono- and/or bicyclic aryl or heteroaryl quinazoline compou ...